FRA:56S1 • FR0013154002
We assign a fundamental rating of 3 out of 10 to 56S1. 56S1 was compared to 21 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of 56S1 have multiple concerns. 56S1 is valied quite expensively at the moment, while it does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.02 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.57 | ||
| Fwd PE | 32.77 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.43 | ||
| EV/EBITDA | 24.31 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
FRA:56S1 (2/13/2026, 7:00:00 PM)
174.85
-3.8 (-2.13%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.57 | ||
| Fwd PE | 32.77 | ||
| P/S | 5.78 | ||
| P/FCF | 45.43 | ||
| P/OCF | 23.29 | ||
| P/B | 4.22 | ||
| P/tB | N/A | ||
| EV/EBITDA | 24.31 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 112.98% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.75% | ||
| Profit Quality | 141.63% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.02 |
ChartMill assigns a fundamental rating of 3 / 10 to 56S1.DE.
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 3 / 10.
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 40.57 and the Price/Book (PB) ratio is 4.22.
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.12% in the next year.